-+ 0.00%
-+ 0.00%
-+ 0.00%

Fosun Pharmaceutical (02196): The drug registration application for compound polyethylene glycol (3350) electrolyte dispersion was approved by the State Drug Administration

Zhitongcaijing·08/03/2026 09:49:07
Listen to the news

Zhitong Finance App News, Fosun Pharmaceutical (02196) issued an announcement. Recently, Suzhou Futaba Pharmaceutical Co., Ltd., a holding subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (hereinafter referred to as the “Company”), a drug registration application for compound polyethylene glycol (3350) electrolyte dispersion (hereinafter referred to as “the drug”) was approved by the State Drug Administration. The approved indications are (1) to treat chronic constipation in children aged 1 to 11; (2) to treat fecal congestion in children aged 5 to 11, that is, intractable constipation accompanied by accumulation of fecal masses in the rectum and/or colon.

As of June 2026, the Group (i.e. the Company and its holding subsidiaries/units, same below) has invested approximately RMB 2.62 million (unaudited) in R&D of this drug at this stage.

According to the latest IQVIA CHPA data, in 2025, sales of compound polyethylene glycol electrolytes scattered in China (excluding Hong Kong, Macao and Taiwan) will be approximately RMB 598 million.